Zona glomerulosa of the adrenal gland in a transgenic strain of rat: a morphologic and functional study. 1994

S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
Department of Medical Semeiology, University of Padua, Italy.

Transgenic rats for the murine Ren-2 gene display high blood pressure, low circulating levels of angiotensin II, and high renin content in the adrenal glands. Moreover, transgenic rats possess an increased aldosterone secretion (maximal from 6 to 18 weeks of age), paralleling the development of hypertension. To investigate further the cytophysiology of the adrenal glands of this strain of rats, we performed a combined morphometric and functional study of the zona glomerulosa of 10-week-old female transgenic rats. Morphometry did not reveal notable differences between zona glomerulosa cells of transgenic and age- and sex-matched Sprague-Dawley rats, with the exception of a marked accumulation of lipid droplets, in which cholesterol and cholesterol esters are stored. The volume of the lipid-droplet compartment underwent a significant decrease when transgenic rats were previously injected with angiotensin II or ACTH. Dispersed zona glomerulosa cells of transgenic rats showed a significantly higher basal aldosterone secretion, but their response to angiotensin II and ACTH was similar to that of Sprague-Dawley animals. Angiotensin II-receptor number and affinity were not dissimilar in zona glomerulosa cells of transgenic and Sprague-Dawley rats. These data suggest that the sustained stimulation of the adrenal renin-angiotensin system in transgenic animals causes an increase in the accumulation in zona glomerulosa cells of cholesterol available for steroidogenesis, as indicated by the expanded volume of the lipid-droplet compartment and the elevated basal steroidogenesis. However, the basal hyperfunction of the zona glomerulosa in transgenic animals does not appear to be coupled with an enhanced responsivity to its main secretagogues, at least in terms of aldosterone secretion.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002788 Cholesterol Esters Fatty acid esters of cholesterol which constitute about two-thirds of the cholesterol in the plasma. The accumulation of cholesterol esters in the arterial intima is a characteristic feature of atherosclerosis. Cholesterol Ester,Cholesteryl Ester,Cholesteryl Esters,Ester, Cholesterol,Ester, Cholesteryl,Esters, Cholesterol,Esters, Cholesteryl
D005260 Female Females
D006929 Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism,Conn Syndrome,Conn's Syndrome,Primary Hyperaldosteronism,Conns Syndrome,Hyperaldosteronism, Primary,Syndrome, Conn,Syndrome, Conn's
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic

Related Publications

S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
May 1998, Molecular and cellular endocrinology,
S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
July 1978, Morphologiai es igazsagugyi orvosi szemle,
S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
March 1985, The Journal of endocrinology,
S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
May 1998, The Journal of endocrinology,
S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
May 1988, The Journal of endocrinology,
S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
January 1967, Archivos de la Fundacion Roux-Ocefa,
S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
October 1974, Endocrinology,
S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
November 1974, Endocrinology,
S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
March 1966, Endocrinology,
S Rocco, and P Rebuffat, and M Cimolato, and G Opocher, and J Peters, and G Mazzocchi, and D Ganten, and F Mantero, and G G Nussdorfer
March 1988, Experimental and clinical endocrinology,
Copied contents to your clipboard!